Article
Oncology
Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C. Semira, Peter Gibbs, Ben Tran, Carmel Pezaro
Summary: Bone metastases and SSEs are common in CRPC patients, yet less than half of patients receive BMAs. The use of BMAs in treatment is associated with a lower rate of SSE occurrence.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, Dwight H. Owen
Summary: In patients with mNSCLC treated with ICIs, the presence of baseline bone metastases was associated with a poorer prognosis, while the use of BMAs did not show a correlation with reduced SREs or improved survival.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Jiyeon Joy Park, Chelsea Wong
Summary: The literature review highlights the clinical efficacy and safety data of pharmacological agents used in managing bone health in individuals affected by cancer. The risk of skeletal-related events, such as bone fracture, bone metastasis, and osteoporosis, is high for individuals with cancers like breast and prostate cancers, multiple myeloma, and other malignancies. Bisphosphonates and RANK-L inhibitor (denosumab) are the main therapy options for managing bone health in this population. Nurses and nurse practitioners should be knowledgeable about the efficacy and appropriate administration of these agents, potential side effects, and timely assessment and interventions to enhance quality of life.
SEMINARS IN ONCOLOGY NURSING
(2022)
Article
Endocrinology & Metabolism
Mark A. Jara, Jeena Varghese, Mimi I. Hu
Summary: Bone metastatic disease can cause serious adverse events. Bone-directed therapies are available to prevent bone-related adverse events, but they can have side effects related to dosage and treatment duration. These side effects range from common and mild symptoms like fever, myalgias, and arthralgias, to less common but more severe side effects like medication-related osteonecrosis of the jaw and atypical femoral fractures. Familiarity with the literature on adverse events associated with bone-directed therapies is important for clinicians.
Article
Endocrinology & Metabolism
Yasutomo Nakai, Tomohiro Kanaki, Akinaru Yamamoto, Ryo Tanaka, Yoshiyuki Yamamoto, Akira Nagahara, Masashi Nakayama, Ken-ichi Kakimoto, Miki Ishibashi, Kazuo Nishimura
Summary: The study found that approximately one-quarter of prostate cancer patients with bone metastasis who were treated with zoledronic acid or denosumab had a risk of developing ARONJ within 5 years. Low serum calcium, use of chemotherapeutic agents, and use of denosumab were identified as independent risk factors for the development of ARONJ.
JOURNAL OF BONE AND MINERAL METABOLISM
(2021)
Article
Multidisciplinary Sciences
Pei-An Fu, Chin-Yao Shen, Shuen-Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung
Summary: Denosumab reduces skeletal-related events (SREs) in breast cancer patients with bone metastases, but its long-term efficacy and safety are limited by lack of real-world data. This retrospective study on 132 denosumab-treated patients found that 11.1% experienced SREs in the first year, with the rate increasing over time. Additionally, 7.6% developed osteonecrosis of the jaw (ONJ), but most of those who resumed denosumab did not experience recurrence of ONJ.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Taewook Kang, Si Young Park, Soon Hyuck Lee, Jong Hoon Park, Seung Woo Suh
Summary: This study compared the effects of DEN and ZOL on postmenopausal women with osteoporosis and found that DEN was associated with greater increase in BMD and TBS, as well as greater inhibition of bone remodeling compared with ZOL.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Dentistry, Oral Surgery & Medicine
Takazumi Yasui, Moemi Kimura, Hiroki Nagamine, Shosuke Yajima, Takeshi Karube, Hitoshi Sato, Seiji Asoda, Satoshi Hara, Katsuhiro Onizawa
Summary: This study evaluated the risk of osteonecrosis of the jaw (ONJ) in patients with prostate cancer and found that castration-resistant prostate cancer (CRPC) and dental extractions are significant risk factors for ONJ development. Additionally, antiresorptive treatment lasting more than 1 year partially mediated between CRPC and the development of ONJ.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
(2021)
Article
Endocrinology & Metabolism
Kristin M. D'Silva, Sara Jane Cromer, Elaine W. Yu, Michael Fischer, Seoyoung C. Kim
Summary: This study found that compared to denosumab, treatment with zoledronic acid for osteoporosis and possibly malignancy-related bone disease is associated with a modestly increased risk of incident atrial fibrillation in the first year of treatment.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Oncology
Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida
Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Aaron P. Mitchell, Akriti Mishra, Katherine S. Panageas, Allison Lipitz-Snyderman, Peter B. Bach, Michael J. Morris
Summary: This study found that more than one-quarter of patients with mCSPC who had no evidence of high osteoporotic fracture risk received BMAs in recent years, suggesting potential overuse.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Review
Oncology
Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, Francesco Massari
Summary: Approximately 90% of patients with metastatic prostate cancer develop bone metastases, leading to various skeletal complications. The use of bone-targeted agents is a major focus in improving survival outcomes for these patients.
Article
Oncology
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki, Michael J. Morris
Summary: The study found that two-thirds of mCRPC patients with bone metastases received bone modifying agents (BMAs) within 180 days after initiating CDT. A greater proportion of patients without bone metastasis may warrant BMA therapy for osteoporotic fracture prevention. Some patients with bone metastasis may be able to delay BMA initiation until CRPC.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Michelle R. Sproat, Bradley Burton, Catherine Burdalski, Timothy Porter, Celia Proctor, Michael Goldenhorn, Kofi Andoh, Steven Gilmore
Summary: Denosumab and zoledronic acid are commonly used drugs for preventing skeletal related events in oncology patients. This study evaluated the use of denosumab and explored opportunities to shift to zoledronic acid and reduce drug costs. The results showed that the use of denosumab was restricted within the health system. Additional education is recommended to limit the use of denosumab, particularly in multiple myeloma patients, to reduce drug costs.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Ling-Ying Wei, Sang-Heng Kok, Yen-Ching Lee, Wei-Yih Chiu, Jai-Jen Wang, Shih-Jung Cheng, Hao-Hueng Chang, Jang-Jaer Lee
Summary: This study aimed to investigate the prognosis of medication-related osteonecrosis of the jaws (MRONJ) in prostate cancer patients who received different types of antiresorptive agents for bone metastasis. The results showed that patients treated with denosumab as the antiresorptive agent, with higher pretreatment levels of CTX and without anemia, had a better treatment outcome for MRONJ.
Article
Oncology
Andrzej Antczak, Dominika Wokolorczyk, Wojciech Kluzniak, Aniruddh Kashyap, Anna Jakubowska, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Tadeusz Debniak, Bartlomiej Masojc, Bohdan Gorski, Tomasz Gromowski, Adam Golab, Andrzej Sikorski, Marcin Slojewski, Bartlomiej Gliniewicz, Tomasz Borkowski, Andrzej Borkowski, Jacek Przybyla, Marek Sosnowski, Bartosz Malkiewicz, Romuald Zdrojowy, Paulina Sikorska-Radek, Jozef Matych, Jacek Wilkosz, Waldemar Rozanski, Jacek Kis, Krzysztof Bar, Hanna Janiszewska, Malgorzata Stawicka, Piotr Milecki, Jan Lubinski, Steven A. Narod, Cezary Cybulskid
EUROPEAN JOURNAL OF CANCER PREVENTION
(2015)
Article
Urology & Nephrology
Karim Fizazi, Christophe Massard, Matthew Smith, Michael Rader, Janet Brown, Piotr Milecki, Neal Shore, Stephane Oudard, Lawrence Karsh, Michael Carducci, Ronaldo Damiao, Huei Wang, Wendy Ying, Carsten Goessl
Article
Oncology
Malgorzata Wierzbicka, Krzysztof Szyfter, Piotr Milecki, Krzysztof Skladowski, Rodryg Ramlau
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
(2015)
Review
Oncology
Tomasz Milecki, Andrzej Antczak, Zbigniew Kwias, Piotr Milecki
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
(2015)
Article
Oncology
Katarzyna Hojan, Magdalena Wojtysiak, Juliusz Huber, Marta Molinska-Glura, Agnieszka Wiertel-Krawczuk, Piotr Milecki
EUROPEAN JOURNAL OF ONCOLOGY NURSING
(2016)
Article
Oncology
Cora Sternberg, Andrew Armstrong, Roberto Pili, Siobhan Ng, Robert Huddart, Neeraj Agarwal, Denis Khvorostenko, Olexiy Lyulko, Arija Brize, Nicholas Vogelzang, Remy Delva, Mihai Harza, Anastasios Thanos, Nicholas James, Patrick Werbrouck, Martin Boegemann, Thomas Hutson, Piotr Milecki, Simon Chowdhury, Enrique Gallardo, Gilberto Schwartsmann, Jean-Christophe Pouget, Frederique Baton, Thore Nederman, Helen Tuvesson, Michael Carducci
JOURNAL OF CLINICAL ONCOLOGY
(2016)
Article
Oncology
Wojciech A. Cieslikowski, Joanna Budna-Tukan, Monika Swierczewska, Agnieszka Ida, Michal Hrab, Agnieszka Jankowiak, Martine Mazel, Michal Nowicki, Piotr Milecki, Klaus Pantel, Catherine Alix-Panabieres, Maciej Zabel, Andrzej Antczak
Article
Oncology
Gerd Fastner, Roland Reitsamer, Bartosz Urbanski, Peter Kopp, Dawid Murawa, Beata Adamczyk, Aldona Karzcewska, Piotr Milecki, Eva Hager, Juliann Reiland, Antonella Ciabattoni, Christiane Matuschek, Wilfried Budach, Kerri Nowell, Claudia Schumacher, Angelika Ricke, Vincenzo Fusco, Cristiana Vidali, Marina Alessandro, Giovanni B. Ivaldi, Ingrid Ziegler, Christoph Fussl, Franz Zehentmayr, Brane Grambozov, Andreas Sir, Wolfgang Hitzl, Umberto Ricardi, Felix Sedlmayer
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Health Care Sciences & Services
Marek Konkol, Maciej Bryl, Marek Fechner, Krzysztof Matuszewski, Pawel Sniatala, Piotr Milecki
Summary: Radiation-induced lung injury is a significant toxicity in thoracic radiotherapy. This study aimed to establish a quantitative grading method by analyzing the changes in lung tissue density using CT scans. The results confirmed a dose-response effect and identified clinical factors that correlated with the degree of lung injury.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Biology
Tomasz Piotrowski, Slav Yartsev, Jaroslaw Krawczyk, Marta Adamczyk, Agata Jodda, Julian Malicki, Piotr Milecki
Summary: A recent study compared the toxicity and disease control outcomes of ultra-hypofractionated radiotherapy (UF-RT) and conventionally fractionated (CF-RT) options. The results showed that UF-RT had similar clinical outcomes to CF-RT, but with a significantly shorter treatment time.
Article
Medicine, General & Internal
Katarzyna Hojan, Eliza Kwiatkowska-Borowczyk, Ewa Leporowska, Piotr Milecki
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ
(2017)
Article
Rehabilitation
Katarzyna Hojan, Eliza Kwiatkowska-Borowczyk, Ewa Leporowska, Maciej Gorecki, Owidia Ozga-Majchrzak, Tomasz Milecki, Piotr Milecki
EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE
(2016)
Review
Urology & Nephrology
Tomasz Golabek, Jonathan Belsey, Tomasz Drewa, Anna Kolodziej, Iwona Skoneczna, Piotr Milecki, Jakub Dobruch, Marcin Slojewski, Piotr L. Chlosta
CENTRAL EUROPEAN JOURNAL OF UROLOGY
(2016)
Article
Oncology
Maria Gloria Torras, Magdalena Fundowicz, Luisa Aliste, Esther Asensio, Anna Maria Boladeras, Josep Maria Borras, Luisa Carualho, Carla Castro, Letizia Deantonio, Ewelina Konstanty, Marco Krengli, Marta Kruszyna, Joana Lencart, Miguel Macia, Susanna Marin, Caries Munoz-Montplet, Carla Pisani, Diana Pinto, Montserrat Puigdemont, Ferran Guedea, Artur Aguiar, Piotr Milecki, Julian Malicki
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
(2017)